LRRK2 and Parkinson disease: It is logical to speculate that these antibodies might therefore find future utility in PD patient-derived neutrophils, potentially as predictive or responsive biomarkers for reporting LRRK2 activity in appropriately powered cohorts of subjects, an analysis the authors are careful to point out has not yet taken place [24].